Product information and disease description Place of product in therapy Disease description Burden of Neovascular age-related macular degeneration

Humanistic burden and health-related quality of life

5 evidence topics · 6 sources

Health utility values by visual acuity in the better-seeing eye

“The mean utility value for the total group with age-related macular degeneration was 0.72 (95% confidence interval [CI], 0.66-0.78) using the time trade-off method and 0.81 (95% CI, 0.76-0.86) using the standard gamble method.” (opens the source at this quote in a new tab)
“Using the time trade-off method correlated with the visual acuity in the better-seeing eye, the results were as follow: group 1, 0.89 (95% CI, 0.82-0.96), group 2, 0.81 (95% CI, 0.73-0.89), group 3, 0.57 (95% CI, 0.47-0.67), group 4, 0.52 (95% CI, 0.38-0.66), and group 5, 0.40 (95% CI, 0.29-0.50).” (opens the source at this quote in a new tab)
“Thus, those patients in group 1 were willing to trade 11% of their remaining lifetime in return for perfect vision in each eye, whereas those in group 5 were willing to trade 60% of their remaining lifetime in return for perfect vision in each eye.” (opens the source at this quote in a new tab)

Vision-related quality of life: NEI VFQ-25 in a treated clinic cohort

“Individuals with mild or moderate visual impairment or blindness at baseline had significantly lower NEI-VFQ-25 scores at follow-up.” (opens the source at this quote in a new tab)
“Those with impaired instrumental ADLs scored 11.62 (p = 0.02), 13.13 (p < 0.0001) and 15.8 (p = 0.0012) points lower in the NEI-VFQ-25, SF-36 physical component score and EQ-5D-5L summary score, respectively.” (opens the source at this quote in a new tab)

Quality of life and mental health during anti-VEGF treatment: systematic reviews

“Depression or depressive symptoms were reported in up to 42% of patients with nAMD. Of 25/63 (40%) studies evaluating quality of life (QoL) and using various tools, eight studies reported composite National Eye Institute Visual Functioning Questionnaire scores following anti-VEGF treatment. Of these, seven reported a statistically significant improvement at the earliest time point measured (Month 3-12) and approximately 50% reported sustained QoL benefits at 12 months.” (opens the source at this quote in a new tab)

“Change on National Eye Institute 25-Item Visual Function Questionnaire score from baseline to month 12 ranged from 0.7 to 4.4.” (opens the source at this quote in a new tab)

Depression and vision-related quality of life in guideline recommendations

“Age-related macular degeneration is associated with depression and reduced vision-related quality of life.” (opens the source at this quote in a new tab)
“Referrals for counseling, vocational rehabilitation, and or peer support groups for patients with depression, anxiety, and loss of independence or employment should be considered.” (opens the source at this quote in a new tab)

Disability-adjusted life-years attributable to AMD

“Similarly, DALYs increased by 91% over the same period, from 0·30 million (95% UI 0·21-0·42) to 0·58 million (0·40-0·80).” (opens the source at this quote in a new tab)